FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity - AP News

The FDA has granted expedited approval to Eli Lilly's weight-loss pill for obesity treatment, marking a significant regulatory milestone for the pharmaceutical company's obesity drug. The accelerated approval process, typically reserved for therapies addressing serious conditions with unmet medical needs, signals the agency's determination that the medication addresses a critical public health gap. Eli Lilly joins competitors like Novo Nordisk in the rapidly expanding weight-loss drug market, which has seen surging demand following the popularity of GLP-1 receptor agonists like Ozempic and Wegovy. The approval expands treatment options for patients with obesity, a condition affecting millions of Americans and associated with increased risk of diabetes, heart disease, and other chronic illnesses. The decision also represents a major commercial opportunity for Eli Lilly as the weight-loss medication sector continues to grow.